• About
  • Subscribe
  • Advertise
  • Contact
Wednesday, May 14, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home News

EssilorLuxottica and GrandVision deal hits stumbling block

by Myles Hume
July 27, 2020
in Business, Company updates & acquisitions, International, News
Reading Time: 3 mins read
A A
GrandVision in Verona, Italy, is one of thousands of stores that could fall under the control of EssilorLuxottica.

GrandVision in Verona, Italy, is one of thousands of stores that could fall under the control of EssilorLuxottica.

Share on FacebookShare on Twitter

EssilorLuxottica has launched legal action against global optician group GrandVision as it seeks information on how the firm has been managed during the COVID-19 pandemic.

In response, GrandVision has initiated arbitration proceedings to confirm it had not breached the agreement, a move EssilorLuxottica regards “as a surprising and obvious attempt … to detract”.

For the past year, EssilorLuxottica has been seeking to acquire a controlling interest in the Dutch-based multinational for up to €7.2 billion (AU$11.8 b) in order to control its more than 7,200 stores across 40 countries and vastly expand its retail presence.

However, the Franco-Italian eyewear giant initiated proceedings against GrandVision in a District Court in Rotterdam, the Netherlands, on 18 July.

“This is to assess the way GrandVision has managed the course of its business during the COVID-19 crisis, as well as the extent to which GrandVision has breached its obligations under the support agreement,” EssilorLuxottica said in a statement.

“Despite repeated requests, GrandVision has not provided this information on a voluntary basis, leaving EssilorLuxottica with no other option but to resort to legal proceedings.”

In response, GrandVision confirmed it had been informed of the court action demanding additional information into its efforts “to mitigate the impact of COVID-19 on its business”.

“GrandVision strongly disagrees with EssilorLuxottica’s demands and has full confidence that these claims will be rejected in court,” the company stated.

It continued: “GrandVision has also received notice from EssilorLuxottica claiming that GrandVision, in relation to the aforementioned COVID-19 actions, is in material breach of its obligations under the support agreement concluded in connection with the envisaged sale by HAL Optical Investments B.V. of its 76.72% ownership interest in GrandVision to EssilorLuxottica.

“GrandVision strongly disagrees with these claims and has responded accordingly.”

Arbitration launched

Later, on 30 July, GrandVision announced it had commenced arbitration proceedings to obtain confirmation that GrandVision is not in material breach of the agreement.

“GrandVision also wants to ensure that EssilorLuxottica complies with its obligations under the support agreement, in particular regarding merger clearance processes,” the company stated.

EssilorLuxottica acknowledged the arbitration, although it said it “regards these … as a surprising and obvious attempt by HAL and GrandVision to detract from GrandVision’s breaches under the support agreement and its failure to provide EssilorLuxottica with required information”.

It continued: “EssilorLuxottica is acting in full compliance with the block trade agreement and the support agreement and any suggestion to the contrary is baseless.”

EssilorLuxottica’s original summary legal proceedings are scheduled to continue at a court hearing on 10 August.

The proposed EssilorLuxottica-GrandVision deal is under review by the European competition authority. It has been unconditionally cleared in the US, Russia and Colombia, and is under review also in Brazil, Chile, Mexico and Turkey.

More reading 

Commission probes proposed EssilorLuxottica-GrandVision acquisition

EssilorLuxottica targets GrandVision takeover

Tags: Brazil.ChileColombiacourtEssilorLuxotticaGrandVisionlegal actionNetherlandsoppticalproceedingsretailRotterdamRussiaTurkeyUS

Related Posts

There were 1,156 allegations to Ahpra of ‘boundary violations’ in 2023-24. 
Image: Pormezz/Shutterstock.com.

Ahpra reforms: Sexual misconduct on register permanently

by Staff Writer
May 13, 2025

Optometrists, ophthalmologists and other registered Australian practitioners proven to have committed sexual misconduct will have this information permanently published against...

American professional golfer Phil Mickelson has co-founded a performance-nutrition company. Image: Shutterstock.com.

Golfing great Mickelson debuts ‘gummies’ for better vision

by Staff Writer
May 12, 2025

A great golf swing won't be too good to you if you can't see where the ball ends up. Amercian...

An AI-based algorithm upscales the acquired topography image from the OS1000 to an impressive 23 megapixels. Images: BOC Instruments.

New corneal topographer from SBM Italy is a powerful precision instrument

by Staff Writer
May 12, 2025

The newly released OS1000 manufactured by SBM Italy is now available in Australia through BOC Instruments. In a release, BOC...

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited